Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Analysis Of Expression Of Programmed Cell Death 1 Ligand 1 (PD-L1) In Malignant Pleural Mesothelioma (MPM)

S. Cedrés, S. Ponce-Aix, J. Zugazagoitia, I. Sansano, A. Enguita, A. Navarro-Mendivil, A. Martínez-Martí, P. Martínez, E. Felip
Published 2015 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background The increasing incidence and poor outcome associated with MPM requires finding effective treatment for this disease. PD1/PD-L1 pathway plays a central role in tumor immune evasion and appears to be predictive and prognostic marker. PD-L1 is expressed in many different human cancers but its role in MPM has yet to be established. The aim of this study is to evaluate the expression of PD-L1 in MPM. Methods 119 MPM patients (p) from two institutions between November 2002 and February 2014 were reviewed. Formalin-fixed, paraffin-embedded tissue was stained with anti-PD-L1 (clone E1L3N). Cases showing more than 1% of tumor cells expression of PD-L1 were considered positive. Results PD-L1 was analyzed in 77 p with tumor tissue available and was positive in 20.7% p (14 samples in membrane, 16 in cytoplasm and 4 in immune infiltrate). PD-L1 intensity was weak in 56.2%, moderate in 25% and strong in 18.7% p. There was a significant relationship between PD-L1 expression and histology (PD-L1 expression 37.5% in no-epithelioid tumor and 13.2% in epithelioid; p=0.033). The median survival in p PD-L1 positive was 4.79 vs 16.3 months in p PD-L1 negative (p=0.012). Conclusions We have shown PD-L1 is expressed in 20% of patients, associated with no epithelioid histology and poor prognostic in MPM. Our results suggest PD-L1 warrants further exploration in selecting p for immunotherapy.
This paper references
10.1158/1538-7445.AM2014-CT105
Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
L. Gandhi (2014)
10.1097/JTO.0b013e318292be18
Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
V. Velcheti (2013)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1183/09031936.00101008
Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells
C. Jackaman (2009)
Tremelimumab for patients with Chemotherapyresistant advanced malignant mesothelioma : an open - label , single arm , phase 2 trial
L Calabro (2013)
10.1016/j.jtcvs.2007.10.026
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
M. Anraku (2008)
10.1016/J.LUNGCAN.2005.03.015
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
R. Flores (2005)
A phase Ib study of MK3475in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck cancer
T Seiwert (2014)
10.1007/978-0-387-88441-7_26
[Pleural mesothelioma].
A. DE GASPERIS (1950)
10.1073/pnas.0611533104
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
10.4049/jimmunol.0901060
Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation1
A. Currie (2009)
10.1200/JCO.2013.31.15_SUPPL.9011
Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab.
J. Weber (2013)
10.1200/JCO.2013.31.15_SUPPL.3000
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
R. Herbst (2013)
10.1016/S0169-5002(00)00217-8
Localised spontaneous regression in mesothelioma -- possible immunological mechanism.
B. Robinson (2001)
10.1371/journal.pone.0088557
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
H. Soliman (2014)
10.1200/JCO.2014.32.15_SUPPL.6011
A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.
T. Seiwert (2014)
10.1016/j.ejcts.2007.09.045
PTEN expression is a strong predictor of survival in mesothelioma patients.
I. Opitz (2008)
10.1158/1078-0432.CCR-10-2275
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1084/JEM.192.7.1027
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1158/1078-0432.CCR-13-3271
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
J. Taube (2014)
10.1016/S0022-5347(18)34858-4
618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
R. H. Thompson (2005)
10.1158/1078-0432.CCR-09-1652
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim (2009)
10.1158/1078-0432.CCR-04-0428
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
J. Konishi (2004)
International Uniona Against Cancer. TNM classification of Malignant Tumors seventh edition
(2009)
10.1158/1078-0432.CCR-12-2063
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
M. Sznol (2013)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1007/s00262-010-0881-6
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
N. Yamada (2010)
10.1038/nri2326
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
10.1002/jso.21901
Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations
O. Rena (2011)
10.1073/pnas.0406351101
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
R. H. Thompson (2004)
CD8+ tumorinfiltrating lymphocytes predict favorable prognosis in malignant pleural mesotheleioma after resection
N Yamada (2010)
10.1111/j.1349-7006.2009.01463.x
Antitumor activity of anti‐C‐ERC/mesothelin monoclonal antibody in vivo
K. Inami (2010)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1016/J.ATHORACSUR.2006.05.070
Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma.
John E Pilling (2007)
10.1016/j.ijsu.2008.04.004
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
S. Neragi-Miandoab (2008)
10.1158/1078-0432.CCR-09-0062
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
R. Kreitman (2009)
10.1158/1078-0432.CCR-04-1469
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Yuichiro Ohigashi (2005)
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
S. Strome (2003)
10.1007/s00262-010-0871-8
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
L. Krug (2010)
10.1158/1078-0432.CCR-13-2702
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
K. Schalper (2014)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.5694/J.1326-5377.2007.TB01315.X
Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the pleura
R. K. Allen (2007)
Lymphocytic infiltration of pleural mesothelioma and its significance for survival.
R. Leigh (1982)
10.1038/nm1517
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
A. Parsa (2007)
10.1146/annurev.immunol.26.021607.090331
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
MK3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer: antitumor activity and association with tumor PD-L1 expression in NSCLC
L Gandhi (2014)
10.1038/labinvest.2013.130
Programmed death ligand-1 expression in non-small cell lung cancer
V. Velcheti (2014)
10.1016/S0169-5002(01)00257-4
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)



This paper is referenced by
10.21037/tlcr.2017.06.01
Novel systemic therapy against malignant pleural mesothelioma.
M. R. Mancuso (2017)
10.1371/journal.pone.0153954
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
M. Ameratunga (2016)
10.1016/j.jtho.2017.03.018
PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
S. Lantuéjoul (2017)
10.2147/CMAR.S151023
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
Pauline du Rusquec (2019)
10.1016/j.lungcan.2016.03.001
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
S. Cedrés (2016)
10.1007/s11864-017-0488-7
Optimal Therapy of Advanced Stage Mesothelioma
M. Disselhorst (2017)
10.18632/oncotarget.25100
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
T. Watanabe (2018)
10.1007/s11033-019-04715-9
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma
N. Sobhani (2019)
10.1158/1078-0432.CCR-18-1231
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
Paulino Tallón de Lara (2018)
10.1586/17476348.2015.1081066
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
10.1016/j.humpath.2017.04.032
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
S. Inaguma (2018)
10.1016/j.jtho.2017.09.1968
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
N. S. Patil (2018)
10.1111/jcmm.13593
Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma
P. Hsu (2018)
10.1007/s00432-020-03457-7
Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis
R. Carosio (2020)
10.1016/J.CLLC.2019.04.010
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
S. Brosseau (2019)
10.1016/j.jtho.2018.08.2036
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
A. Tsao (2018)
10.1016/j.intimp.2017.08.017
Prognostic value of tumor PD‐L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer
Q. Wang (2017)
10.1016/S1470-2045(17)30621-6
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
N. van Zandwijk (2017)
10.2147/LCTT.S102113
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
10.1007/978-3-030-16884-1_8
Tissue and Circulating Biomarkers in Mesothelioma
Paolo Andrea Zucali (2019)
10.1016/j.maturitas.2017.04.014
The mechanisms tumor cells utilize to evade the host's immune system.
Nyanbol Kuol (2017)
10.2217/LMT.15.23
Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma
Alistair M. Cook (2015)
10.21037/TLCR.2020.03.38
Clinical significance of histologic subtyping of malignant pleural mesothelioma.
L. Brčić (2020)
10.21037/tlcr.2019.11.29
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
10.1158/1078-0432.CCR-16-0844
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
Licun Wu (2016)
10.3389/fonc.2019.01366
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
G. Chu (2019)
10.1016/j.ctarc.2020.100260
Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland.
D. Vizcaya (2020)
10.1016/j.jtho.2020.03.006
Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.
J. Remon (2020)
10.1007/978-3-319-52619-5_36-1
Radiation Therapy in Mesothelioma
J. Willmann (2019)
10.1007/s13665-017-0179-7
Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future
A. Scherpereel (2017)
CMAR_A_151023 4297..4312
M. Robert (2019)
10.3389/fonc.2020.00343
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
L. Cantini (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar